Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

HIV therapy

This page shows the latest HIV therapy news and features for those working in and with pharma, biotech and healthcare.

HIV meeting hears progress towards vaccine and cure

HIV meeting hears progress towards vaccine and cure

There’s still a lot of work to do to extend the benefits of drug therapy to people around the world, and vaccines could make a critical contribution to controlling HIV ... Eliminating the HIV reservoir. The main reason drug therapy for HIV can control

Latest news

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Rivals Gilead's Biktarvy. ViiV Healthcare now has approval on both sides of the Atlantic for two-drug HIV therapy Dovato after a green light from the EMA. ... It claims the two-drug regimens can reduce drug exposure and side effects, as well as improve

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    The HIV therapy market is also likely to be affected by the arrival of generic versions of lamivudine. ... Gilead’s GS-6207 is a novel HIV-1 capsid inhibitor is seen as a potential component in a future long-acting therapy.

  • GSK, J&J say monthly injection keeps HIV controlled GSK, J&J say monthly injection keeps HIV controlled

    The long-acting antiretroviral therapy (ART) could mean that more patients adhere to the treatment regimen needed to suppress HIV, and avoid the risk of skipped doses that can help viral ... In three patients on the injectable (1%) there was a failure to

  • MSD claims EU approval for two HIV products MSD claims EU approval for two HIV products

    Company battles back against dominant Gilead and GSK. Merck &Co/MSD’s market share in HIV has been on the slide thanks to tough competition from GlaxoSmithKline and Gilead, but it ... Isentress is used as an add-on therapy to other HIV drugs and

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    The injection could rival Gilead’s single-tablet therapy. GlaxoSmithKline’s bid to develop an alternative to daily dosing of HIV drugs has made further progress, with new data backing the ... combinations GSK is hoping will simplify HIV therapy for

More from news
Approximately 2 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    This type of combination therapy is known as highly active antiretroviral therapy (HAART), and remains the recommended treatment for HIV today. ... Ipsos' HIV Therapy Monitor data shows that the top reason for prescribing an STR is convenience.

  • Top of the charts

    Client:University of Liverpool. Agency:eMedFusion, a division of the KP360 Group. Campaign:HIV iCharts. ... HIV iCharts was launched with great success at the 10th International Congress on Drug Therapy in HIV Infection in November 2010, reaching number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • emotive boosts its client services team emotive boosts its client services team

    Fay Lepley also joins the agency as an account executive and has had experience working in PR and healthcare communications across several therapy areas including cardiovascular, diabetes and HIV. ... Completing the new team line-up, Sabrina Mohamed has

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March. ... I have had the pleasure to work with an exceptional team and am proud of how the

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • emotive takes Gold and Silver at PM Society Digital Awards 2018!

    innovation. emotive used an innovative technology platform in a live meetings setting to engage an audience of top HIV clinicians. ... Commenting on the news, Senior Account Director and HIV lead for emotive,  Andrew Parry, said, “The team at emotive

  • emotive. expands client services team

    as an Account Manager. A Biology graduate from the University of Leeds, Rob has experience working in infectious diseases, rare diseases and medical devices, amongst other therapy areas. ... HIV.  . Lizzie Nayman, Client Services Director for emotive.

  • A fast-growing client services team at emotive.

    Fay has previous experience working in PR and healthcare communications across a number of therapy areas, including cardiovascular, diabetes and HIV. ... Also with a Biomedical Science degree, Sabrina worked in healthcare public relations, specifically

  • Marketing strategy in complex environments

    Whilst not new, this approach is becoming increasingly effective for certain therapy areas, particularly  oncology. ... Another popular combination therapy is  HAART: Highly Active Antiretroviral Therapy  used for HIV where six major types of drugs

  • Infographic: HIV Market Snapshot

    Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients  are currently treated with a STR ... Therapy Watch HIV patient data is collected bi-monthly from

More from PMHub
Approximately 1 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Quick links

Infographics

Multimedia